Metraipolis › archive › dc_df864d677ff9
Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study — Europe PMC PMID:40961902
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40961902
- DOI
- 10.1016/j.breast.2025.104573
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T01:02:30.016Z
- SHA-256 of the archived text
a9885a67df92b622716fe332692ca088cc32dfe7efd2aa67669d5be846485575- Stable URL of this page
https://metraipolis.com/documento/dc_df864d677ff9
How to cite
Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study — Europe PMC PMID:40961902 — Europe PMC (en), https://europepmc.org/article/MED/40961902 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_df864d677ff9 (Metraipolis archive dc_df864d677ff9, sha256 a9885a67df92b622716fe332692ca088cc32dfe7efd2aa67669d5be846485575)
BibTeX
@misc{dcdf864d677ff9,
title = {Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study — Europe PMC PMID:40961902},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40961902},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_df864d677ff9; sha256 a9885a67df92b622716fe332692ca088cc32dfe7efd2aa67669d5be846485575},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40961902. Agents can read the archived copy with the MCP tool read_document.